For decades, the biotech innovation engine has produced extraordinary breakthroughs in cancer, rare diseases, and metabolic disorders. Yet across vast areas of medicine from preeclampsia to sarcopenia, dry eye disease, and neurodegeneration, progress has stalled. These are not rare conditions - they are common, costly, and catastrophic, affecting millions, but still without transformative therapies. Why? This session convenes leaders who have chosen to tackle diseases others abandoned as too complex or too commercially uncertain. Together, they will dissect where innovation has faltered in disease biology, technological advancements, or clinical application, and explore what’s finally changing that equation. Attendees will leave with a clearer view of where the biggest opportunities and the toughest roadblocks truly lie, and how new scientific and technological breakthroughs can help biotech reclaim the impossible.